Acutaas Chemicals delivered strong financial performance in FY26. **Business Performance:** Revenue from Operations surged to ₹1,339.4 Cr, a 33% year-on-year increase.

Profit After Tax more than doubled to ₹356.4 Cr, marking a 122% jump.

Pharmaceutical Intermediates remains the dominant segment, contributing 88% of revenue.

The company also reported a robust EBITDA margin of 35.9% and healthy ROCE/ROE at 39.3% and 32.5% respectively. **Growth Drivers or Strategy:** The company is strategically expanding, focusing on CDMO opportunities in pharmaceuticals and pioneering new-edge segments like semiconductor and battery chemicals.

Significant capex of over ₹1,000 Cr is planned until FY30, including capacity expansion in pharma and establishing advanced facilities for semiconductor chemicals via a South Korea JV. **Recent Developments:** Notable updates include the rebranding to Acutaas Chemicals Ltd. and the formation of Indichem Inc., a joint venture in South Korea for advanced semiconductor chemicals.

The company also inaugurated Phase 1 of its Battery Chemicals manufacturing facility. **Key Financial Metrics:** FY26 Revenue: ₹1,339.4 Cr (+33% YoY). PAT: ₹356.4 Cr (+122% YoY). EBITDA Margin: 35.9%. **Management Commentary / Outlook:** Management is investing aggressively in sustainable future growth, earmarking over ₹1,000 Cr for capex until FY30 across pharma, semiconductor, and battery chemical segments, alongside R&D and solar power initiatives.